1. Home
  2. IZEA vs RNTX Comparison

IZEA vs RNTX Comparison

Compare IZEA & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IZEA Worldwide Inc.

IZEA

IZEA Worldwide Inc.

HOLD

Current Price

$3.15

Market Cap

62.9M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.80

Market Cap

65.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IZEA
RNTX
Founded
2006
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
62.9M
65.3M
IPO Year
2010
2017

Fundamental Metrics

Financial Performance
Metric
IZEA
RNTX
Price
$3.15
$0.80
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
52.0K
407.3K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
100.00
44.16
EPS
N/A
N/A
Revenue
$20,099,695.00
N/A
Revenue This Year
$20.81
N/A
Revenue Next Year
$14.86
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.00
$0.69
52 Week High
$5.86
$2.18

Technical Indicators

Market Signals
Indicator
IZEA
RNTX
Relative Strength Index (RSI) 37.02 44.33
Support Level N/A $0.69
Resistance Level $3.79 $1.05
Average True Range (ATR) 0.15 0.06
MACD -0.03 0.01
Stochastic Oscillator 18.88 59.81

Price Performance

Historical Comparison
IZEA
RNTX

About IZEA IZEA Worldwide Inc.

IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: